A recent study published in the British Journal of Nutrition reveals promising results regarding the use of daily prebiotic fiber supplements in patients
with pre-diabetes, suggesting significant improvements in insulin sensitivity and other vital health markers.
"Pre-diabetes affects over 7 million individuals in the UK," says Dr. Thomas Gurry, CEO at myota. "Our findings have shown that prebiotic fiber represents a
promising and efficacious fast-acting treatment to manage pre-diabetes."
Conducted over 24 weeks with 66 prediabetic participants, the study, led by scientists from myota and CRO Lindus Health, utilised a diverse prebiotic blend.
"The results of our study suggest that this natural diverse prebiotic fiber supplement could be taken to reverse pre-diabetes and to prevent or slow the onset
of type 2 diabetes," says Dr. Caitlin Hall, Head of Research at myota.
Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients.
Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said.
"The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear.
"This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach,
MHRA Interim Executive Director, Healthcare Quality and Access.